FDA Approves First mRNA Flu Vaccine mFLUSIVA for Adults 50+ With 26.6% Greater Effectiveness

The FDA approved the first mRNA flu vaccine, mFLUSIVA, in August 2026 for adults 50 and older, offering a new option that showed 26.6% greater relative effectiveness than standard-dose shots in a large clinical trial.

The FDA approved the first mRNA flu vaccine for adults 50 and older based on a trial enrolling more than 40,000 participants.

For decades, the annual flu shot has relied on a predictable, months-long manufacturing process: grow the virus in eggs or cell cultures, inactivate it, and package the pieces that teach the immune system what to fight.

The first mRNA influenza vaccine to reach the U.S. market, branded mFLUSIVA, upends that timeline. Nebraska Medicine reported the approval, noting the technology allows manufacturers to swap viral targets almost as easily as changing a LEGO brick — a critical advantage when circulating strains drift away from the strains selected months earlier.

How the two vaccines teach the body differently

Traditional flu vaccines introduce inactivated viral proteins directly. The immune system recognizes these foreign proteins, builds antibodies, and stands ready for a real infection. The mRNA approach skips the protein factory altogether. Instead, it delivers genetic instructions that tell the recipient’s own cells to produce a harmless piece of the virus — the antigen — triggering the same immune memory. The messenger RNA degrades quickly, but the immune lesson persists.

FDA Approves Moderna’s mFlusiva, First mRNA Flu Vaccine — TODAY

“Think of it like building a house with LEGO® bricks,” said Amber Tyler, MD, a primary care physician at Nebraska Medicine. “If one brick is blue, but I really want it to be red, I can simply switch them out to create the new version.”

That flexibility matters because the World Health Organization and FDA must select vaccine strains in late winter for a fall rollout, a gap during which the virus can mutate.

The effectiveness data that drove approval

The FDA based its decision on a key trial enrolling more than 40,000 adults aged 50 and older. In the agency’s clinical review, mFLUSIVA demonstrated 26.6% greater relative effectiveness at preventing laboratory-confirmed influenza illness compared with a standard-dose inactivated vaccine. For older adults, who bear the brunt of severe flu seasons, that margin translates into fewer hospitalizations and complications — though no vaccine eliminates infection risk entirely.

FDA approves first-ever mRNA flu vaccine for older Americans — LiveNOW from FOX

“Getting vaccinated doesn’t mean you absolutely won’t get the flu,” Tyler said. “There’s still a chance you’ll get sick, but the illness will likely be much less severe.”

Regulators found safety profile favorable

Regulators characterized the safety profile as generally favorable. Most reactions were mild to moderate and resolved within a day or two. Common side effects included injection-site soreness, redness, or swelling; muscle aches; headache; fatigue; and low-grade fever.

Swollen lymph nodes were also reported more frequently than with traditional shots — a known immune-system signal. Severe allergic reactions remain rare with either platform, but clinicians advise seeking immediate care for difficulty breathing, lip or tongue swelling, dizziness, or fainting after any vaccination.

FDA Approves First mRNA Flu Vaccine: Why It Matters — Minority Health Partners

Who is eligible and the egg-allergy question

Adults 50 to 64 received full FDA approval based on the efficacy data. For those 65 and older, the agency granted accelerated approval, requiring additional studies to confirm benefits against high-dose and adjuvanted vaccines already standard for that age group. The vaccine is not authorized for anyone under 50.

Because mFLUSIVA is produced without eggs, it joins Flublok (approved for ages 9 and older) and Flucelvax (approved for 6 months and older) as egg-free alternatives. The Centers for Disease Control and Prevention maintains that people with egg allergies can safely receive any age-appropriate flu vaccine, but the mRNA option adds another needle in the haystack for those who prefer to avoid egg-based products entirely.

FDA Approves mFLUSIVA: The Truth About the First mRNA Flu Shot — The Deep Dive News

No combination flu COVID vaccine available

Despite shared mRNA technology, mFLUSIVA targets only influenza. “There are no current combination flu and COVID vaccines available,” Tyler said. Patients can receive separate flu and COVID-19 shots during the same visit, a practice the CDC endorses for convenience and timely protection.

Tyler’s bottom line: talk to your provider about which vaccine fits your history, but do not delay immunization waiting for a specific brand. “Any flu vaccine is better than no flu vaccine,” she said. “So, if only one type is available and you’re able to get it, you should.” She recommends vaccination by the end of October, or sooner if local flu activity picks up.